References
- Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: Treatment of Epilepsy. Epilepsy Behav 2001; 2:A1–50
- Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology 1984;34(9):1252–5
- Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol 1986; 43(3):263–5
- Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975;8(5):337–41
- Geradin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm 1976;4(6):521–35
- Eichelbaum M, Kothe KW, Hoffman F, von Unruh GE. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 1979;26(3):366–71
- Jensen PK, Moller A, Gram L, Jensen NO, Dam M. Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurol Scand 1990;82(2):135–7
- Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6(5):592–9
- Macphee GJ, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med J 1985;61(719):779–83
- Hoppener RJ, Kuyer A, Meijer JW, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21(4):341–50
- Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984;41(8):830–4
- Riva R, Albani F, Ambrosetto G, Contin M, Cortelli P, Perucca E, et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984;25(4):476–81
- Garnett WR, Levy B, McLean AM, Zhang Y, Couch RA, Rudnic EM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998;39(3):274–9
- Mirza WU, Rak IW, Thadani VM, Cereghino JJ, Garnett WR, Brown LM, et al. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998;51(6):1727–9
- Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261(22):3273–7
- McLean A, Browne S, Zhang Y, Slaughter E, Halstenson C, Couch R. The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. J Clin Pharmacol 2001;41(2):183–6
- Garnett WR. Carbamazepine. In Muphy JE, ed. Clinical Pharmacokinetics, 2nd edn. Washington, DC: American Society of Health-Systems Pharmacist, 2001:97–117
- Kutt H, Penry JK. Usefulness of blood levels of antiepileptic drugs. Arch Neurol 1974;31(5):283–8